US equities |
SPCX $166.32 ▲+4.63% NVDA $236.67 ▲+1.16% MU $1,063.46 ▼-1.06% TSLA $377.75 ▲+1.93% MSFT $525.95 ▲+1.63% SNDK $1,708.61 ▼-0.66% INTC $117.05 ▼-1.91% META $745.11 ▲+2.34%
FinancialContent

20/20 Biolabs, Inc. - Common Stock (NQ:AIDX)

0.3789 -0.0011 (-0.29%)
Delayed Quote Updated: 11:17 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 20/20 Biolabs, Inc. - Common Stock

News headline image
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
From 20/20 Biolabs Inc.
Via GlobeNewswire
Monday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
What's Going On With 20/20 Biolabs Stock? ↗
Shares of 20/20 Biolabs, Inc. (NASDAQ: AIDX) are trading lower Tuesday after the company announced that it entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare. 
Via Benzinga
News headline image
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies
Protein Biomarkers May Play an Important Role in Overcoming Limitations of Circulating Tumor DNA for Screening Early-Stage Cancers 
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time
From 20/20 Biolabs Inc.
Via GlobeNewswire